NYSE:BHC

Bausch Health Companies Stock Forecast, Price & News

$29.31
-0.48 (-1.61 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.97
$29.54
50-Day Range
$27.43
$32.70
52-Week Range
$14.86
$34.80
Volume3.54 million shs
Average Volume4.00 million shs
Market Capitalization$10.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.74
30 days | 90 days | 365 days | Advanced Chart
Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies logo

About Bausch Health Companies

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

231st out of 2,100 stocks

Pharmaceutical Preparations Industry

111th out of 831 stocks

Analyst Opinion: 2.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

Is Bausch Health Companies a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Bausch Health Companies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View analyst ratings for Bausch Health Companies
or view top-rated stocks.

What stocks does MarketBeat like better than Bausch Health Companies?

Wall Street analysts have given Bausch Health Companies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bausch Health Companies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bausch Health Companies
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) posted its quarterly earnings data on Monday, May, 3rd. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. The company earned $2.03 billion during the quarter, compared to analysts' expectations of $2.08 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 352.44% and a negative net margin of 12.66%. The company's revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.88 EPS.
View Bausch Health Companies' earnings history
.

How has Bausch Health Companies' stock price been impacted by Coronavirus?

Bausch Health Companies' stock was trading at $18.45 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHC shares have increased by 58.9% and is now trading at $29.31.
View which stocks have been most impacted by COVID-19
.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion.

What price target have analysts set for BHC?

9 brokers have issued 12 month price targets for Bausch Health Companies' stock. Their forecasts range from $17.00 to $55.00. On average, they anticipate Bausch Health Companies' share price to reach $34.80 in the next year. This suggests a possible upside of 18.7% from the stock's current price.
View analysts' price targets for Bausch Health Companies
or view top-rated stocks among Wall Street analysts.

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 65, Pay $3.74M)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 65, Pay $2.1M)
  • Ms. Christina M. Ackermann, Exec. VP, Gen. Counsel & Head of Commercial Operations (Age 56, Pay $1.31M)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 59, Pay $2.16M)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 49)
  • Dr. Robert F. Butz, VP of Medical & Scientific Affairs
  • Mr. Arthur J. Shannon, Sr. VP and Head of Investor Relations & Global Communications
  • Mr. Michael McMyne, VP of Sales
  • Ms. Stacey Williams, VP of Marketing
  • Ms. Kelly Webber, Sr. VP & Chief HR Officer

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies CEO Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among Bausch Health Companies' employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different institutional and retail investors. Top institutional investors include Glenview Capital Management LLC (4.36%), Morgan Stanley (1.97%), Laurion Capital Management LP (1.75%), Royal Bank of Canada (1.55%), Price T Rowe Associates Inc. MD (1.48%) and Fiera Capital Corp (0.96%). Company insiders that own Bausch Health Companies stock include Amy B Wechsler, Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Mark C Mckenna, Sam Eldessouky, Schutter Richard U De and William D Humphries.
View institutional ownership trends for Bausch Health Companies
.

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Permian Investment Partners LP, Canyon Capital Advisors LLC, Renaissance Technologies LLC, Redwood Capital Management LLC, Glenview Capital Management LLC, BlackRock Inc., Lakewood Capital Management LP, and Price T Rowe Associates Inc. MD. Company insiders that have sold Bausch Health Companies company stock in the last year include Amy B Wechsler, Christina Ackermann, Sam Eldessouky, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies
or view top insider-selling stocks.

Which major investors are buying Bausch Health Companies stock?

BHC stock was purchased by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Factorial Partners LLC, Thompson Siegel & Walmsley LLC, Voloridge Investment Management LLC, BNP Paribas Arbitrage SA, Royal Bank of Canada, Hillsdale Investment Management Inc., and Putnam Investments LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Schutter Richard U De, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies
or or view top insider-buying stocks.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $29.31.

How much money does Bausch Health Companies make?

Bausch Health Companies has a market capitalization of $10.50 billion and generates $8.03 billion in revenue each year. The company earns $-560,000,000.00 in net income (profit) each year or $3.99 on an earnings per share basis.

How many employees does Bausch Health Companies have?

Bausch Health Companies employs 21,600 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.bauschhealth.com.

Where are Bausch Health Companies' headquarters?

Bausch Health Companies is headquartered at 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.